Literature DB >> 26384545

The Nlrp3 Inflammasome Suppresses Colorectal Cancer Metastatic Growth in the Liver by Promoting Natural Killer Cell Tumoricidal Activity.

Jeremy Dupaul-Chicoine1, Azadeh Arabzadeh2, Maryse Dagenais1, Todd Douglas3, Claudia Champagne4, Alexandre Morizot4, Ian Gaël Rodrigue-Gervais4, Valérie Breton2, Sara L Colpitts5, Nicole Beauchemin6, Maya Saleh7.   

Abstract

The crosstalk between inflammation and tumorigenesis is now clearly established. However, how inflammation is elicited in the metastatic environment and the corresponding contribution of innate immunity pathways in suppressing tumor growth at secondary sites are poorly understood. Here, we show that mice deficient in Nlrp3 inflammasome components had exacerbated liver colorectal cancer metastatic growth, which was mediated by impaired interleukin-18 (IL-18) signaling. Control of tumor growth was independent of differential cancer cell colonization or proliferation, intestinal microbiota effects, or tumoricidal activity by the adaptive immune system. Instead, the inflammasome-IL-18 pathway impacted maturation of hepatic NK cells, surface expression of the death ligand FasL, and capacity to kill FasL-sensitive tumors. Our results define a regulatory signaling circuit within the innate immune system linking inflammasome activation to effective NK-cell-mediated tumor attack required to suppress colorectal cancer growth in the liver.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Fas; NLRP3; caspase-1; cell death; colorectal cancer; immunosurveillance; inflammasome; innate immunity; interleukin-18; metastasis; natural killer (NK) cells

Mesh:

Substances:

Year:  2015        PMID: 26384545     DOI: 10.1016/j.immuni.2015.08.013

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  101 in total

Review 1.  The contrasting roles of inflammasomes in cancer.

Authors:  Qin He; Yu Fu; Dean Tian; Wei Yan
Journal:  Am J Cancer Res       Date:  2018-04-01       Impact factor: 6.166

Review 2.  Inflammasomes and intestinal inflammation.

Authors:  N Zmora; M Levy; M Pevsner-Fishcer; E Elinav
Journal:  Mucosal Immunol       Date:  2017-04-12       Impact factor: 7.313

Review 3.  Converging roles of caspases in inflammasome activation, cell death and innate immunity.

Authors:  Si Ming Man; Thirumala-Devi Kanneganti
Journal:  Nat Rev Immunol       Date:  2015-12-14       Impact factor: 53.106

Review 4.  Metabolic regulation of inflammasomes in inflammation.

Authors:  Qiuli Yang; Ruichen Liu; Qing Yu; Yujing Bi; Guangwei Liu
Journal:  Immunology       Date:  2019-04-08       Impact factor: 7.397

Review 5.  Inflammasomes and adaptive immune responses.

Authors:  Katherine A Deets; Russell E Vance
Journal:  Nat Immunol       Date:  2021-02-18       Impact factor: 25.606

Review 6.  Inflammasomes in Myeloid Cells: Warriors Within.

Authors:  Sushmita Jha; W June Brickey; Jenny Pan-Yun Ting
Journal:  Microbiol Spectr       Date:  2017-01

Review 7.  NLRP3 inflammasome in cancer and metabolic diseases.

Authors:  Bhesh Raj Sharma; Thirumala-Devi Kanneganti
Journal:  Nat Immunol       Date:  2021-03-11       Impact factor: 25.606

Review 8.  Role of inflammasome activation in tumor immunity triggered by immune checkpoint blockers.

Authors:  M Segovia; S Russo; M R Girotti; G A Rabinovich; M Hill
Journal:  Clin Exp Immunol       Date:  2020-05       Impact factor: 4.330

9.  Linking cancer-induced Nlrp3 inflammasome activation to efficient NK cell-mediated immunosurveillance.

Authors:  Maryse Dagenais; Maya Saleh
Journal:  Oncoimmunology       Date:  2016-04-22       Impact factor: 8.110

Review 10.  The role of intestinal bacteria in the development and progression of gastrointestinal tract neoplasms.

Authors:  Kosuke Mima; Shuji Ogino; Shigeki Nakagawa; Hiroshi Sawayama; Koichi Kinoshita; Ryuichi Krashima; Takatsugu Ishimoto; Katsunori Imai; Masaaki Iwatsuki; Daisuke Hashimoto; Yoshifumi Baba; Yasuo Sakamoto; Yo-Ichi Yamashita; Naoya Yoshida; Akira Chikamoto; Takatoshi Ishiko; Hideo Baba
Journal:  Surg Oncol       Date:  2017-07-21       Impact factor: 3.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.